Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Prior to a chimpanzee adenovirus-based (ChAd63) malarial vaccine trial, sera were collected to assess ChAd63-specific neutralizing antibody titers in Banfora (Burkina Faso). The low neutralizing antibody titers reported in both adults and children (median titers, 139.1 and 35.0, respectively) are encouraging for the potential use of ChAd63 as a malarial vaccine vector.

Original publication

DOI

10.1128/CVI.00723-13

Type

Journal article

Journal

Clin Vaccine Immunol

Publication Date

06/2014

Volume

21

Pages

901 - 903

Keywords

Adenoviruses, Simian, Adolescent, Adult, Animals, Antibodies, Neutralizing, Antibodies, Viral, Burkina Faso, Child, Child, Preschool, Cohort Studies, Humans, Infant, Malaria Vaccines, Malaria, Falciparum, Middle Aged, Pan troglodytes, Young Adult